regge

Robert Egge

Executive Director

The Centers for Medicare & Medicaid Services (CMS) issued a draft decision that essentially denies coverage of treatments targeting amyloid for Alzheimer's disease, including aducanumab, the first FDA-approved therapy to address the underlying biology of Alzheimer's disease. 

To explain the challenges and concerns posed by the draft decision memo, the Alzheimer's Association and AIM convened a group of experts for a Congressional briefing. You can watch the briefing below: 

0:02: Welcome and Overview by Robert Egge, chief public policy officer, Alzheimer's Association
0:55: Summary of Recent Developments and Key Features of the Draft Decision Memo by Robert Egge
6:12: Observations on the Draft Decision Memo by Dr. Mark McClellan, former administrator of the Centers for Medicare & Medicaid Services (CMS) and former commissioner of the U.S. Food and Drug Administration (FDA)
20:04: Q&A with Dr. Mark McClellan and Robert Egge
23:31: How the CMS Proposal Inappropriately Addresses the Entire Class of Treatments by Dr. Joanne Pike, president, Alzheimer's Association
29:00: Uncertain Clinical Effectiveness Poses Key Policy Choice by Robert Egge
32:55: Patient Perspective by Dale Rivard (Minnesota), living with Mild Cognitive Impairment (MCI)
39:42: CMS Proposal Takes Wrong Approach in Commendable Pursuit of Safety by Robert Egge
42:28: A Deeper Understanding of the Class Safety Profile by Dr. Maria Carrillo, chief science officer, Alzheimer's Association
52:11: The Proposal's Potential Impact on Access and Equity by Dr. Carl V. Hill, chief diversity, equity and inclusion officer, Alzheimer's Association
56:18: Closing by Robert Egge, chief public policy officer, Alzheimer's Association
56:50: Patient Perspective by Phil Gutis (Pennsylvania), living with younger-onset Alzheimer's disease

 
CMS must improve this draft decision. They must ensure access for all who could benefit from FDA-approved treatments. Learn more and take action.
 

regge

Robert Egge

Executive Director

Robert Egge is the chief public policy officer of the Alzheimer's Association and the executive director of the Alzheimer's Impact Movement (AIM), a separately incorporated advocacy affiliate of the...

Read Full Bio